Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
24 August, 2017 01:08 IST
Zydus receives approval from USFDA for Mesalamine suppositories
Source: IRIS | 11 Aug, 2017, 05.12PM
Comments  |  Post Comment

Zydus Cadila has received the tentative approval from the USFDA to market Mesalamine Suppositories for rectal use, 1000 mg.

Mesalamine is used to treat an inflammatory bowel disease, such as ulcerative colitis. It will be produced at the group's Topical plant at Ahmedabad.

The group now has more than 140 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of the company gained Rs 17.55, or 3.77%, to settle at Rs 482.95. The total volume of shares traded was 401,757 at the BSE (Friday).





Cadila Healthcare Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Lupin launches generic Seroquel XR tablets in US - 23-Aug-2017 16:08
Reliance Capital offers ESOP's worth Rs 3 bn - 23-Aug-2017 15:03
Zydus Cadila gets USFDAs final approval for Ziprasidone HCl capsules - 23-Aug-2017 12:27
Glenmark Pharma gets nod for Triamcinolone Acetonide ointment - 23-Aug-2017 09:58
Cambridge Technology acquires new client in AI - 23-Aug-2017 09:55
Ramco Systems bags order from global top 5 aircraft manufacturer - 22-Aug-2017 14:38
Tata Power JV synchronizes 186 MW Georgia Hydro Project in record time - 22-Aug-2017 14:03
JMD Ventures' arm inks pact with Amazon - 22-Aug-2017 11:07
Zydus Cadilla gets USFDAs final nod for Pindolol tablets - 22-Aug-2017 10:58
Dr Reddy's to get up to USD 32.5 mn milestone payments for DFD-06 - 22-Aug-2017 10:33
Eros Int'l Media's promoter completes sale of 11.8 mn shares - 22-Aug-2017 10:22
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer